Montelucaste Tetrafarma (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1 on airway smooth muscle and inflammatory cells. This inhibition prevents leukotrienes from causing bronchoconstriction, mucus production, and inflammation, thereby improving airway patency and reducing allergic symptoms.

The specific dose of Montelucaste Tetrafarma is determined by the prescribing healthcare professional based on the patient’s age, weight, severity of disease, and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for montelukast in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against any possible risks and discuss these considerations with the patient before prescribing. Breastfeeding mothers should consult their physician regarding continuation of therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients who need additional control of leukotriene‑mediated inflammation or who experience exercise‑induced bronchoconstriction, complementing other inhaled therapies.

Montelucaste Tetrafarma should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with water; do not crush, chew, or split the tablet unless specifically instructed.

Serious adverse events, though rare, include severe allergic reactions such as anaphylaxis, neuropsychiatric effects like mood changes or suicidal thoughts, and hepatic injury. Patients should seek immediate medical attention if they experience rash, swelling, difficulty breathing, or significant changes in mood.

Montelucaste Tetrafarma is contraindicated in individuals with known hypersensitivity to montelukast or any of the tablet’s excipients. It should also be avoided in patients who have experienced severe allergic reactions to leukotriene receptor antagonists.